Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Expression analysis of human ErbB3 on HEK293/Human ErbB3 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human ErbB3 Stable Cell Line or negative control cell using PE-labeled anti-human ErbB3 antibody.
Immobilized Biotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human NRG1 Beta 1, Fc Tag, premium grade (Cat. No. NR1-H5268) with a linear range of 0.2-3 ng/mL (QC tested).
The purity of Mouse ErbB3, His Tag (Cat. No. ER3-M52H5) is more than 85% and the molecular weight of this protein is around 75-110 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Pharmaceutical Co Ltd | 泰瑞沙, Tagrisso | Mainland China | Carcinoma, Non-Small-Cell Lung | Astrazeneca Ab | 2015-11-13 | Uterine Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Meningeal Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Brain metastases; Esophageal adenocarcinoma; Cholangiocarcinoma; Lymphoma; Glioma; Endometrial Neoplasms; Thyroid Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Adenocarcinoma of Lung; Liver Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Skin Neoplasms; Colonic Neoplasms; Glioblastoma; Multiple Myeloma; Urinary Bladder Neoplasms | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Recombinat humanized HER3-targeting antibody | Phase 1 Clinical | Shanghai Institute Of Biological Products Co Ltd | Solid tumours | Details | |
Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
GSK-2849330 | GSK-2849330 | Glaxosmithkline Plc | Details | ||
JK-07 | JK-07 | Shenzhen Salubris Pharmaceuticals Co Ltd | Details | ||
Patritumab | AMG-888; U3-1287 | Amgen Inc, Daiichi Sankyo Co Ltd | Details | ||
AV-203 | AV-203; CAN-017 | Phase 1 Clinical | Aveo | Neoplasms | Details |
MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Molecular Partners Ag | Details | ||
Recombinant Human Neuromodulin 1-Anti-HER3 Antibody Fusion Protein(Salubris) | SAL-007 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Heart Failure | Details |
Recombinant human ErbB3 fragment vaccine (Zensun) | rhErbB3-f | Phase 1 Clinical | Zensun (Shanghai) Sci&Tech Co Ltd | Neoplasms | Details |
Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Elgemtumab | NOV-6; LJM-716 | Phase 1 Clinical | Novartis Pharma Ag, Morphosys Ag | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Esophageal Squamous Cell Carcinoma | Details |
SIBP-03 | SIBP-03 | Phase 1 Clinical | Shanghai Institute Of Biological Products Co Ltd | Neoplasms | Details |
Barecetamab | ISU-104 | Phase 1 Clinical | Isu Abxis Co Ltd | Solid tumours | Details |
HMBD-001 | HMBD-001 | Phase 2 Clinical | Hummingbird Bioscience | Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
KTN-3379 | CDX-3379; KTN-3379 | Phase 2 Clinical | Medimmune | Squamous Cell Carcinoma of Head and Neck; Neoplasms; Breast Neoplasms; Thyroid Neoplasms | Details |
Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Tesevatinib | XL-647; KD-020; KD-019; EXEL-7647 | Phase 2 Clinical | Exelixis Inc | Neoplasms; Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
BL-B01D1 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Neoplasms, Fibroepithelial; Solid tumours; Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Urologic Neoplasms; Gastrointestinal Neoplasms | Details | |
Seribantumab | MM-121; SAR-256212; 1N3L70MDFX (UNII code) | Phase 2 Clinical | Merrimack Pharmaceuticals Inc | Sarcoma; Adenocarcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Uterine Neoplasms; Gallbladder Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Ovarian Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Urinary Bladder Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Kidney Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
Patritumab Deruxtecan | U3-1402 | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Breast Neoplasms; Colorectal Neoplasms; Brain metastases; Carcinoma, Non-Small-Cell Lung | Details |
Zenocutuzumab | MCLA-128 | Phase 2 Clinical | Merus Nv | Solid tumours; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Izalontamab | SI-B001; SI-1X6.4 | Phase 3 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Head and Neck Neoplasms; Solid tumours; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.